ID

30850

Description

Preemptive Strike With Bortezomib in Multiple Myeloma Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00657553

Link

https://clinicaltrials.gov/show/NCT00657553

Keywords

  1. 6/27/18 6/27/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

June 27, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT00657553

Eligibility Multiple Myeloma NCT00657553

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with multiple myeloma currently or previously enrolled on uark 98-026 and currently event-free at the time of the evaluation.
Description

Multiple Myeloma | Study Subject Participation Status | Event Free of

Data type

boolean

Alias
UMLS CUI [1]
C0026764
UMLS CUI [2]
C2348568
UMLS CUI [3,1]
C0441471
UMLS CUI [3,2]
C0332296
performance status of 0-2 based of swog criteria
Description

Performance status SWOG Criteria

Data type

boolean

Alias
UMLS CUI [1,1]
C1518965
UMLS CUI [1,2]
C1519429
UMLS CUI [1,3]
C0243161
previously documented platelet count > 75,000/ul within a 35 days prior to enrollment
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
previously documented peripheral absolute neutrophil count >1,000/ul within 35 days prior to enrollment.
Description

Absolute neutrophil count Peripheral blood

Data type

boolean

Alias
UMLS CUI [1,1]
C0948762
UMLS CUI [1,2]
C0229664
adequate renal function
Description

Renal function

Data type

boolean

Alias
UMLS CUI [1]
C0232804
signed informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
female subject is post-menopausal or willing to use acceptable birth control
Description

Postmenopausal state | Gender Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
male subjects agree to use acceptable method of contraceptive
Description

Gender Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
hypersensitivity to bortezomib, boron, or mannitol
Description

Hypersensitivity Bortezomib | Hypersensitivity Boron | Mannitol allergy

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1176309
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0006030
UMLS CUI [3]
C0571922
female subject is pregnant or breastfeeding
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
experienced myocardial infraction within 6 months prior to enrollment
Description

Myocardial Infarction

Data type

boolean

Alias
UMLS CUI [1]
C0027051
received other investigational new drugs within 14 days before enrollment
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
received any anti-myeloma therapy within 14 days
Description

Therapeutic procedure Multiple Myeloma

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0026764
serious medical or psychiatric illness likely to interfere with participation in this clinical study
Description

Illness Serious Interferes with Study Subject Participation Status | Serious mental illness Interferes with Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C2348568
UMLS CUI [2,1]
C3841614
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C2348568
diagnosed or treated for another malignancy within 3 years of enrollment
Description

Cancer Other Diagnosed | Cancer Other Treated

Data type

boolean

Alias
UMLS CUI [1,1]
C1707251
UMLS CUI [1,2]
C0011900
UMLS CUI [2,1]
C1707251
UMLS CUI [2,2]
C1522326

Similar models

Eligibility Multiple Myeloma NCT00657553

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma | Study Subject Participation Status | Event Free of
Item
diagnosed with multiple myeloma currently or previously enrolled on uark 98-026 and currently event-free at the time of the evaluation.
boolean
C0026764 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
C0441471 (UMLS CUI [3,1])
C0332296 (UMLS CUI [3,2])
Performance status SWOG Criteria
Item
performance status of 0-2 based of swog criteria
boolean
C1518965 (UMLS CUI [1,1])
C1519429 (UMLS CUI [1,2])
C0243161 (UMLS CUI [1,3])
Platelet Count measurement
Item
previously documented platelet count > 75,000/ul within a 35 days prior to enrollment
boolean
C0032181 (UMLS CUI [1])
Absolute neutrophil count Peripheral blood
Item
previously documented peripheral absolute neutrophil count >1,000/ul within 35 days prior to enrollment.
boolean
C0948762 (UMLS CUI [1,1])
C0229664 (UMLS CUI [1,2])
Renal function
Item
adequate renal function
boolean
C0232804 (UMLS CUI [1])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Postmenopausal state | Gender Contraceptive methods
Item
female subject is post-menopausal or willing to use acceptable birth control
boolean
C0232970 (UMLS CUI [1])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Gender Contraceptive methods
Item
male subjects agree to use acceptable method of contraceptive
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Bortezomib | Hypersensitivity Boron | Mannitol allergy
Item
hypersensitivity to bortezomib, boron, or mannitol
boolean
C0020517 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0006030 (UMLS CUI [2,2])
C0571922 (UMLS CUI [3])
Pregnancy | Breast Feeding
Item
female subject is pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Myocardial Infarction
Item
experienced myocardial infraction within 6 months prior to enrollment
boolean
C0027051 (UMLS CUI [1])
Investigational New Drugs
Item
received other investigational new drugs within 14 days before enrollment
boolean
C0013230 (UMLS CUI [1])
Therapeutic procedure Multiple Myeloma
Item
received any anti-myeloma therapy within 14 days
boolean
C0087111 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
Illness Serious Interferes with Study Subject Participation Status | Serious mental illness Interferes with Study Subject Participation Status
Item
serious medical or psychiatric illness likely to interfere with participation in this clinical study
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C3841614 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
Cancer Other Diagnosed | Cancer Other Treated
Item
diagnosed or treated for another malignancy within 3 years of enrollment
boolean
C1707251 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C1707251 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial